Details for New Drug Application (NDA): 083921
✉ Email this page to a colleague
NDA 083921 describes ELIXOPHYLLIN, which is a drug marketed by Forest Labs and Nostrum Labs Inc and is included in four NDAs. It is available from one supplier. Additional details are available on the ELIXOPHYLLIN profile page.
The generic ingredient in ELIXOPHYLLIN is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
The generic ingredient in ELIXOPHYLLIN is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
Summary for 083921
| Tradename: | ELIXOPHYLLIN |
| Applicant: | Forest Labs |
| Ingredient: | theophylline |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 083921
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 200MG | ||||
| Approval Date: | Jul 31, 1984 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
